IMRN — Immuron Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1660046 ·
Last close
$0.87
Market Cap
$7.03M
52W High
$1.99
52W Low
$0.68
ADV30
25,837
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 13,151,698 | 9,017,814 | 1,986,671 |
| Dec 2025 | — | — | — | — | 15,137,584 | 9,995,328 | 2,061,145 |
| Jun 2025 | — | — | — | — | 10,129,842 | 2,830,526 | 2,060,787 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-84,970,154
Inventory
$2,273,848
Receivables
$1,409,118
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,713,601
EBITDA
$-3,959,737
Free Cash Flow
$-2,319,899
Enterprise Value
$2,874,972
Total Cash
$9,017,814
Total Debt
$189,543
Shares Out
8,071,202
Trailing EPS
$-0.37
Book Value
$0.98
ROE
-40.2%
ROA
-21.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Jun 2025 | 7,287,002 | -5,356,731 | -5,215,987 | 10,129,842 | 2,060,787 | 8,069,055 | — |
| Jun 2024 | 4,902,865 | -5,215,839 | -6,936,957 | 15,549,969 | 2,840,525 | 12,709,444 | — |
| Jun 2023 | 1,804,705 | -3,406,520 | -3,786,507 | 21,988,182 | 2,371,346 | 19,616,836 | — |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XCUR | EXICURE, INC. | $7.07M | $1.08 | — |
| MBRX | Moleculin Biotech, Inc. | $6.96M | $6.83 | — |
| LGVN | Longeveron Inc. | $6.83M | $2.11 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.71M | $1.88 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.37M | $4.70 | — |
News headlines (Yahoo Finance, 1h cache)
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
2026-11-10 11:00 · Yahoo
Emerging Growth Research Reports Continued Revenue Growth at Immuron
2026-11-04 23:10 · Yahoo
Immuron continued quarterly sales growth
2026-10-27 10:00 · Yahoo
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
2026-10-22 22:27 · Yahoo
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
2026-09-04 14:50 · Yahoo
Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement
2026-09-04 13:53 · Yahoo
Immuron to launch PROIBS® in the United States
2026-09-04 10:00 · Yahoo
Presenting on Emerging Growth Conference 97 Day 1 on October 28; Register to live stream
2026-10-27 11:00 · Yahoo
Travelan® Phase 2 Study Results Published
2026-10-13 10:00 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-09-04 19:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.